TABLE 2.
HI antigen | Group | Anti-IBV HI antibody titer (log2) (geometric mean ± standard error) at days of ageb |
|||||
---|---|---|---|---|---|---|---|
0 | 4 | 7 | 14 | 21 | 28 | ||
M41 | I | 9.2 ± 0.374A | 8.2 ± 0.970A | 7.4 ± 0.400A | 5 ± 0.000B | 5 ± 0.548A | 4 ± 0.447A |
II | 9.2 ± 0.374A | 8.8 ± 0.374A | 7.4 ± 0.400A | 6.4 ± 0.510A | 5.4 ± 0.400A | 4.4 ± 0.400A | |
III | 9.2 ± 0.374A | 7.2 ± 0.374A | 6.4 ± 0.748A | 4.8 ± 0.200B | 4 ± 0.632A | 2 ± 0.632B | |
CR88 | I | 8.4 ± 0.400A | 7.8 ± 0.374A | 6.8 ± 0.490A | 5 ± 0.316A | 6.8 ± 0.583A | 4.4 ± 0.678B |
II | 8.4 ± 0.400A | 8.4 ± 0.245A | 6.8 ± 0.374A | 5.8 ± 0.200A | 7 ± 0.548A | 8.2 ± 0.583A | |
III | 8.4 ± 0.400A | 7.6 ± 0.400A | 7.4 ± 0.245A | 4.6 ± 0.600A | 3.4 ± 0.245B | 1.8 ± 0.490C | |
Q1 | I | 7 ± 0.316A | 3 ± 0.316A | 2.4 ± 0.245A | 2.2 ± 0.200B | 4.4 ± 0.510A | 4.4 ± 0.510B |
II | 7 ± 0.316A | 3 ± 0.678A | 3.4 ± 0.400A | 3.8 ± 0.374A | 5 ± 0.548A | 5.6 ± 0.245A | |
III | 7 ± 0.316A | 3.4 ± 0.316A | 2.2 ± 0.200A | 2 ± 0.000B | 2 ± 0.000B | 2 ± 0.000C |
Both groups were again vaccinated with CR88 at 14 days of age. One group (group III) was kept as a control.
Significant differences between the groups (n = 5 per group) for each homologous as well as heterologous antigen for each interval are represented by different letters (P < 0.05).